Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.

摘要: Core-binding factor acute myeloid leukemia (CBF-AML) – including AML with t(8;21) and inv(16) accounts for about 15% of adult is associated a relatively favorable prognosis. Nonetheless, relapse incidence may reach 40% in these patients. In this context, identification prognostic markers considered great interest. Due to similarities between their molecular features, inv(16)-AML are usually grouped reported together clinical studies. However, considerable experimental evidences have highlighted that they represent two distinct entities should be separately further This review summarizes recent laboratory findings particular subset how could used improve management patients routine practice.